The NSCLC current strategies to develop effective treatments include the study, to a great depth, of different molecular targets such as K-RAS (Kirsten Rat Sarcoma), the epidermal growth factor receptor (EGFR), phosphatidylinositol 3-kinase (PI3Ks), mechanistic target of rapamycin (mTOR), epidermal growth factor receptor 2 (ErbB2), vascular epidermal growth factor receptor (VEGFR), mesenchymal-epithelial transition factor or hepatocyte growth factor receptor (c-MET), anaplastic lymphoma kinase (ALK) and v-Raf murine sarcoma viral oncogene homolog B (BRAF) and others. The gene discussed is MET; the disease is non-small cell lung carcinoma.